Stayble Therapeutics AB Cash Flow Conversion Efficiency
Stayble Therapeutics AB cash flow conversion efficiency. Based on the latest financial reports, Stayble Therapeutics AB (STABL) has a cash flow conversion efficiency ratio of -0.194x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-1.34 Million ≈ $-144.31K USD) by net assets (Skr6.92 Million ≈ $744.92K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Stayble Therapeutics AB (2016–2025)
Cash flow conversion efficiency of Stayble Therapeutics AB from 2016 to 2025. This chart illustrates how Stayble Therapeutics AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Stayble Therapeutics AB stock quote for real-time trading data and today's change.
Stayble Therapeutics AB Cash Flow Conversion Ratio Explained
Stayble Therapeutics AB cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Stayble Therapeutics AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Stayble Therapeutics AB ranked by their cash flow conversion efficiency. Also see STABL company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Niraj Ispat Industries Limited
NSE:NIRAJISPAT
|
0.006x |
|
Distribution Finance Capital Holdings PLC
LSE:DFCH
|
0.088x |
|
Sonovia Ltd
TA:SONO
|
-1.025x |
|
Fsport AB
ST:FSPORT
|
-0.057x |
|
Polledo S.A.
BA:POLL
|
0.130x |
|
Nexoptic Technology Corp
V:NXO
|
-0.011x |
|
Moovly Media Inc
V:MVY
|
0.016x |
|
Infield Minerals Corp
V:INFD
|
-0.006x |
Annual Cash Flow Conversion Efficiency for Stayble Therapeutics AB (2016–2025)
The table below shows the annual cash flow conversion efficiency of Stayble Therapeutics AB from 2016 to 2025. Review Stayble Therapeutics AB (STABL) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr6.92 Million ≈ $744.92K |
Skr-6.72 Million ≈ $-723.29K |
-0.971x | +54.50% |
| 2024-12-31 | Skr6.87 Million ≈ $739.64K |
Skr-14.67 Million ≈ $-1.58 Million |
-2.134x | -49.66% |
| 2023-12-31 | Skr16.51 Million ≈ $1.78 Million |
Skr-23.54 Million ≈ $-2.53 Million |
-1.426x | +12.45% |
| 2022-12-31 | Skr15.28 Million ≈ $1.64 Million |
Skr-24.89 Million ≈ $-2.68 Million |
-1.628x | -572.99% |
| 2021-12-31 | Skr39.81 Million ≈ $4.28 Million |
Skr-9.63 Million ≈ $-1.04 Million |
-0.242x | +84.31% |
| 2020-12-31 | Skr15.55 Million ≈ $1.67 Million |
Skr-23.98 Million ≈ $-2.58 Million |
-1.542x | -57.46% |
| 2019-12-31 | Skr-295.44K ≈ $-31.79K |
Skr289.39K ≈ $31.14K |
-0.980x | -28.49% |
| 2018-12-31 | Skr7.11 Million ≈ $765.43K |
Skr-5.42 Million ≈ $-583.53K |
-0.762x | -140.22% |
| 2017-12-31 | Skr8.25 Million ≈ $887.43K |
Skr-2.62 Million ≈ $-281.63K |
-0.317x | -152.05% |
| 2016-12-31 | Skr11.06 Million ≈ $1.19 Million |
Skr-1.39 Million ≈ $-149.87K |
-0.126x | -- |
About Stayble Therapeutics AB
Stayble Therapeutics AB (publ) a clinical pharmaceutical company, developing an injection-based treatments for disc herniation. It develops STA363, an injection into the disc that targets chronic low back and leg pain. The company was incorporated in 2015 and is based in Gothenburg, Sweden.